Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EBIT (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed EBIT for 7 consecutive years, with -$1.0 million as the latest value for Q3 2025.

  • For Q3 2025, EBIT rose 10.82% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$3.6 million, up 38.68%, while the annual FY2024 figure was -$3.6 million, 71.99% up from the prior year.
  • EBIT hit -$1.0 million in Q3 2025 for Cyclerion Therapeutics, up from -$1.7 million in the prior quarter.
  • Across five years, EBIT topped out at $502000.0 in Q4 2024 and bottomed at -$16.2 million in Q2 2021.
  • Average EBIT over 5 years is -$5.9 million, with a median of -$3.3 million recorded in 2023.
  • Year-over-year, EBIT tumbled 33.13% in 2023 and then skyrocketed 127.97% in 2024.
  • Cyclerion Therapeutics' EBIT stood at -$14.3 million in 2021, then surged by 68.93% to -$4.5 million in 2022, then surged by 59.71% to -$1.8 million in 2023, then surged by 127.97% to $502000.0 in 2024, then tumbled by 300.4% to -$1.0 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$1.0 million, -$1.7 million, and -$1.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.